Figure 2:

Transverse dynamic T1-weighted MR images obtained in bevacizumab-treated rat after intravenous administration of albumin-(Gd-DTPA)₃₀ at a dose of 0.03 mmol gadolinium per kilogram of body weight show MDA-MB 435 breast cancer (arrow) implanted in mammary zone persistently enhancing for at least 60 minutes, with the strongest tumor enhancement in the rim. Arrowhead = inferior vena cava. Pre = before contrast medium administration. (Note the incidental finding of bright signal intensity from the bowel and its contents.) The relatively low but measurable enhancement of the tumor center may reflect the normally high interstitial pressure within the tumor core, which limits local blood flow and transendothelial diffusion of the contrast medium.